Hepatosplenic T-cell Lymphoma Arising in Patients with Immunodysregulatory Disorders: A Study of 7 Patients Who Did Not Receive TNF- α Inhibitor Therapy and Literature Review

Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive extranodal T-cell lymphoma that can arise in patients with underlying immune disorders. Others have suggested that tumor necrosis factor alpha (TNF- α) inhibitor therapy for immune disorders increases the risk of HSTCL. To assess for a potential relationship between HSTCL and the use of TNF-α inhibitors, we searched for patients with HSTCL and underlying immune disorders at our institution. We identified 7 patients with a median age of 38 year s.

Source: Annals of Diagnostic Pathology - October 17, 2016 Category: Pathology Authors: Mariko Yabe, L. Jeffrey Medeiros, Yahya Daneshbod, Masoud Davanlou, Carlos E. Bueso-Ramos, Elisa J. Moran, Ken H. Young, Roberto N. Miranda Source Type: research